Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21873002 | 0.86 | CYP3A4 (0.45) | FGFR1FGFR4CYP2C9CYP3A4MET | |
| SCHEMBL21873065 | 0.78 | CSF1R (0.47) | FGFR1FGFR4METGPR84CSF1R | |
| SCHEMBL27677373 | 0.76 | CSF1R (0.60) | FGFR1FGFR4CYP2C9CYP3A4MET | |
| SCHEMBL21872975 | 0.75 | CCNB2 (0.38) | METCSF1RCDK2CCNT1CCNA2 | |
| SCHEMBL21872991 | 0.74 | MAP2K1 (0.43) | CDK2CCNT1CCNA2CDK9RET | |
| SCHEMBL21872979 | 0.73 | CYP3A4 (0.47) | CYP2C9CYP3A4CYP2C19CSF1RKIT | |
| SCHEMBL1887952 | 0.72 | CYP2C9 (0.79) | FGFR1FGFR4CYP2C9CYP3A4MET | |
| SCHEMBL857205 | 0.71 | MET (0.60) | FGFR1FGFR4CYP2C9CYP3A4MET | |
| SCHEMBL14198425 | 0.71 | GPR84 (0.67) | FGFR1FGFR4CYP2C9CYP3A4MET | |
| SCHEMBL21873139 | 0.70 | CYP3A4 (0.39) | CYP2C9CYP3A4CYP2C19CSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| EP-3643715-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643715-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CSF1R, CSF3R, FSHR | FGFR1 109/4885FGFR4 444/4885CYP2C9 3017/4885 |
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | CSF1R, CSF3R, FSHR | FGFR1 109/4885FGFR4 444/4885CYP2C9 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.